What happened
The Department of Energy’s Office of Science, the National Institutes of Health, and the philanthropic research organization Biohub announced a joint Memorandum of Understanding to develop an open biological data foundation for predictive AI models. The agreement pools the computational resources of DOE’s national laboratories, NIH’s health data and imaging assets, and Biohub’s AI tools and biomedical infrastructure. DOE will invest more than $500 million over five years, covering data collection, AI analytics, advanced imaging, modeling, and high‑performance computing. Biohub will match that commitment with $500 million for its Virtual Biology Initiative (VBI), a global effort to generate multimodal datasets and tools for building “virtual cells.” The partnership is framed as part of the DOE “Genesis Mission,” which seeks to leverage AI‑ready biological data and automated experiments to accelerate discovery in medicine and biotechnology. Both agencies emphasized that the data and models will be openly available to the worldwide scientific community.
On Oct. 9, 2026, DOE’s Office of Science, NIH, and Biohub signed a Memorandum of Understanding to jointly fund and coordinate the creation of an open biological data platform for AI‑driven predictive modeling. The agreement outlines a five‑year, $1 billion investment split evenly between DOE and Biohub, with DOE focusing on high‑performance computing, data acquisition, and advanced imaging, while Biohub leads the Virtual Biology Initiative to generate multimodal datasets and AI tools.
The partnership leverages DOE’s national laboratory network—including Oak Ridge, Argonne, and Lawrence Berkeley—for large‑scale computation and measurement, NIH’s extensive health data repositories and imaging facilities for real‑world biological context, and Biohub’s expertise in AI development and biomedical research infrastructure. The collaboration is positioned as a core component of DOE’s Genesis Mission, which seeks to accelerate scientific breakthroughs through AI‑ready data and automated experimentation.
Both DOE and Biohub have pledged $500 million each over the next five years. Funding will support data collection from cell cultures, organoids, and animal models; development of AI analytics pipelines; creation of standardized data formats; and the construction of virtual cell models that can predict cellular responses to genetic, chemical, or environmental perturbations. The initiative emphasizes open access, inviting researchers worldwide to contribute to and use the datasets.
Why it matters
Creating an open, AI‑driven data foundation for biology could transform how researchers study disease and develop therapies. Predictive models that accurately simulate cellular responses would let scientists run virtual experiments, dramatically cutting the time and cost of drug discovery and reducing reliance on animal testing. By combining DOE’s supercomputing power with NIH’s clinical and imaging datasets, the initiative aims to produce multimodal, high‑resolution data that current AI models lack, potentially unlocking new insights into complex diseases such as cancer, neurodegeneration, and infectious illnesses. The $1 billion public investment signals strong governmental commitment to AI‑enabled biotechnology and positions the United States as a leader in open, data‑centric science, which may attract additional private‑sector collaboration and accelerate translation of research into clinical applications.
Predictive biology has long been limited by fragmented, siloed datasets and insufficient computational tools. By unifying massive, multimodal data streams with exascale computing, the partnership could produce the first truly generalizable models of cellular behavior, enabling in‑silico hypothesis testing before costly wet‑lab experiments.
Open data and models lower barriers for academic and industry researchers, fostering a collaborative ecosystem that can accelerate therapeutic discovery, reduce drug development timelines, and improve reproducibility. The initiative also aligns with broader federal goals to modernize biomedical research infrastructure and maintain U.S. leadership in AI‑driven science.
The $1 billion public investment underscores the strategic importance of AI in national health security, potentially informing rapid response to emerging pathogens and supporting medicine initiatives that require large, high‑quality biological datasets.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
Which component of an AI application is the machine-learning model itself?
What to watch next
Key milestones to monitor include the first public release of VBI multimodal datasets, benchmarks of predictive cell models against experimental results, and the rollout of AI analytics pipelines on DOE’s exascale computers. Watch for announcements of partner institutions joining the effort, as the MOU invites global scientific participation. Policy observers should track how open‑data licensing and intellectual‑property frameworks are defined, given the mix of federal, philanthropic, and private contributions. Finally, follow any early‑stage applications of the predictive models in drug target validation or therapeutic screening, which would demonstrate the partnership’s practical impact.
Release schedule of the first VBI multimodal datasets and accompanying metadata standards.
Performance benchmarks of early predictive cell models against experimental validation studies.
Announcements of additional research institutions, biotech firms, or international partners joining the effort.
Development of licensing and data‑sharing policies that balance open access with privacy and IP considerations.
Early applications of the predictive models in drug target identification, toxicology screening, or personalized medicine pilots.